257 related articles for article (PubMed ID: 8718427)
1. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients.
Lund B; Hansen OP; Neijt JP; Theilade K; Hansen M
Anticancer Drugs; 1995 Dec; 6 Suppl 6():61-2. PubMed ID: 8718427
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.
Lund B; Hansen OP; Theilade K; Hansen M; Neijt JP
J Natl Cancer Inst; 1994 Oct; 86(20):1530-3. PubMed ID: 7932808
[TBL] [Abstract][Full Text] [Related]
3. A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum.
Sehouli J; Stengel D; Oskay G; Blohmer J; Kaubitzsch S; Lichtenegger W
J Obstet Gynaecol Res; 2003 Jun; 29(3):123-31. PubMed ID: 12841693
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine in advanced breast cancer.
Possinger K
Anticancer Drugs; 1995 Dec; 6 Suppl 6():55-9. PubMed ID: 8718426
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.
D'Agostino G; Amant F; Berteloot P; Scambia G; Vergote I
Gynecol Oncol; 2003 Mar; 88(3):266-9. PubMed ID: 12648573
[TBL] [Abstract][Full Text] [Related]
6. Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer.
Kodaz H; Hacibekiroglu I; Turkmen E; Erdogan B; Elpen C; Uzunoglu S; Cicin I
Tumori; 2015; 101(1):36-40. PubMed ID: 25702671
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.
Friedlander M; Millward MJ; Bell D; Bugat R; Harnett P; Moreno JA; Campbell L; Varette C; Ripoche V; Kayitalire L
Ann Oncol; 1998 Dec; 9(12):1343-5. PubMed ID: 9932166
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of gemcitabine in ovarian cancer.
von Minckwitz G; Bauknecht T; Visseren-Grul CM; Neijt JP
Ann Oncol; 1999 Jul; 10(7):853-5. PubMed ID: 10470434
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.
Sehouli J; Stengel D; Oskay G; Camara O; Hindenburg HJ; Klare P; Blohmer J; Heinrich G; Elling D; Ledwon P; Lichtenegger W;
Ann Oncol; 2002 Nov; 13(11):1749-55. PubMed ID: 12419747
[TBL] [Abstract][Full Text] [Related]
10. Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer.
Niu J; Kundranda MN; Markman M; Farley J
Eur J Gynaecol Oncol; 2017; 38(1):40-44. PubMed ID: 29767862
[TBL] [Abstract][Full Text] [Related]
11. Safety profile of gemcitabine.
Tonato M; Mosconi AM; Martin C
Anticancer Drugs; 1995 Dec; 6 Suppl 6():27-32. PubMed ID: 8718422
[TBL] [Abstract][Full Text] [Related]
12. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM
Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178
[TBL] [Abstract][Full Text] [Related]
13. Advanced breast cancer: a phase II trial with gemcitabine.
Carmichael J; Possinger K; Phillip P; Beykirch M; Kerr H; Walling J; Harris AL
J Clin Oncol; 1995 Nov; 13(11):2731-6. PubMed ID: 7595731
[TBL] [Abstract][Full Text] [Related]
14. Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma.
Suprasert P; Cheewakriangkrai C; Manopunya M
Asian Pac J Cancer Prev; 2012; 13(2):517-20. PubMed ID: 22524817
[TBL] [Abstract][Full Text] [Related]
15. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial.
Van Kooten M; Traine G; Cinat G; Cazap E; Comba AZ; Vicente H; Sena S; Nievas OR; Orlando M
Br J Cancer; 1999 Nov; 81(5):846-9. PubMed ID: 10555756
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
Faivre S; Le Chevalier T; Monnerat C; Lokiec F; Novello S; Taieb J; Pautier P; Lhommé C; Ruffié P; Kayitalire L; Armand JP; Raymond E
Ann Oncol; 2002 Sep; 13(9):1479-89. PubMed ID: 12196375
[TBL] [Abstract][Full Text] [Related]
17. Single-agent gemcitabine is active in previously treated metastatic breast cancer.
Spielmann M; Llombart-Cussac A; Kalla S; Espié M; Namer M; Ferrero JM; Diéras V; Fumoleau P; Cuvier C; Perrocheau G; Ponzio A; Kayitalire L; Pouillart P
Oncology; 2001; 60(4):303-7. PubMed ID: 11408796
[TBL] [Abstract][Full Text] [Related]
18. Phase II studies of gemcitabine for non-small cell lung cancer in Japan.
Fukuoka M; Takada M; Yokoyama A; Kurita Y; Niitani H
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-42-S7-46. PubMed ID: 9194479
[TBL] [Abstract][Full Text] [Related]
19. Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
Goff BA; Thompson T; Greer BE; Jacobs A; Storer B;
Am J Obstet Gynecol; 2003 Jun; 188(6):1556-62; discussion 1562-4. PubMed ID: 12824993
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane.
Raspagliesi F; Zanaboni F; Vecchione F; Hanozet F; Scollo P; Ditto A; Grijuela B; Fontanelli R; Solima E; Spatti G; Scibilia G; Kusamura S
Oncology; 2004; 67(5-6):376-81. PubMed ID: 15713993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
